Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma

NCT07511504 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced Hepatocellular Carcinoma
Stage III Hepatocellular Carcinoma AJCC v8
Stage IV Hepatocellular Carcinoma AJCC v8
Unresectable Hepatocellular Carcinoma

Interventions

PROCEDURE: Angiogram
PROCEDURE: Biopsy Procedure
PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
BIOLOGICAL: Durvalumab
PROCEDURE: Magnetic Resonance Imaging
PROCEDURE: Single Photon Emission Computed Tomography
BIOLOGICAL: Tremelimumab
PROCEDURE: Yttrium-90 Microsphere Radioembolization
DRUG: Zanzalintinib

Sponsor

OHSU Knight Cancer Institute

Collaborators

[object Object]
[object Object]